Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 12,298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infusion Procedure Clear all

Conditions: HIV -1 Infection
Interventions: TMB-365, TMB-380, Baseline ART; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more

Conditions: Low Grade Ovarian Serous Adenocarcinoma
Interventions: nab-Sirolimus, Fulvestrant; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Non-Small Cell Lung Cancer
Interventions: Paclitaxel, Gemcitabine, Avastin; Drug · Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Depression
Interventions: Infliximab, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neoplasms
Interventions: ADH -1 (Exherin™); Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Supportive Care, Survey Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions: Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more

Conditions: Type1 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Atlanta, Georgia • Saint Louis Park, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Decision Support System, Usual Care; Device · Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colorectal Cancer Screening
Interventions: Water infusion, Air insufflation; Procedure
Lead sponsor: East Bay Institute for Research and Education; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Mather, California

Conditions: Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Interventions: tocilizumab; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: 2 Years to 16 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastric Cancer Adenocarcinoma Metastatic
Interventions: Docetaxel, cetuximab, oxaliplatin; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 41 more

Conditions: Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
Interventions: Tappt; Device
Lead sponsor: Mercy Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: New Orleans, Louisiana • Chevy Chase, Maryland • New York, New York + 3 more

Conditions: Healthy
Interventions: PF-05230907, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
Interventions: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York • Huntersville, North Carolina

Conditions: Castrate Resistant Prostate Cancer (CRPC)
Interventions: BPX-101, AP1903; Biological · Drug
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Tirofiban, Placebo; Drug
Lead sponsor: Dr David Hasan, M.D.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions: ASP1240, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes
Interventions: Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging; Other · Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 30 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Rectal Cancer, Adenocarcinoma of the Rectum
Interventions: 5-fluorouracil, bevacizumab, erlotinib, External beam radiation therapy (EBRT); Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions: daptomycin; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 19 Years to 74 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Torrance, California

Conditions: Cervical Cancer
Interventions: Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan; Drug · Radiation · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Post-operative Pain
Interventions: Ropivacaine; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Royal Oak, Michigan • Troy, Michigan

Search by objective public record fields.

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

Inflammation-Induced CNS Glutamate Changes in Depression

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

Weighted Blanket Use to Reduce Anxiety in Oncology Patients

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

A Study of LY900014 in a Medtronic Pump

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance

Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes

Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

Initial Local Anesthetic Dose With Continuous Interscalene Analgesia